{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:52:57Z","timestamp":1765961577712,"version":"3.40.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>HIV infection is associated with an increased risk of morbidity and mortality from vaccine preventable infections. This research describes, in the context of changing patient demographics, the seroprevalence of vaccine preventable viral infections among attendees of the largest centre for HIV positive patients in Ireland.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Baseline serum IgG results for measles, mumps, rubella, varicella zoster virus (VZV) &amp; hepatitis A, as well as hepatitis B sAg, cAb and sAb results, were retrieved for 2534 clinic attendees\u00a0attending in 2018. Results were available for between 990 and 2363 attendees (39\u201393%), depending on the test, and were compared with 2013 clinic data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was a 35% increase in attendees in 2018 when compared to 2013. The largest increase was in attendees of South American origin. In 2018, males accounted for 73% of the entire cohort and the HIV acquisition risk for 48% of attendees was MSM. 47% of attendees were originally from Ireland. Among those tested, 33% were susceptible to at least one component of the MMR vaccine. 5% were VZV non-immune (significantly associated with younger age and the acquisition risk status of injection drug use). 21% were hepatitis A non-immune (significantly associated with younger age and being of European or South American origin). 32% were hepatitis B cAb seropositive (significantly associated with older age, injection drug use status and being originally from Africa). 3% demonstrated hepatitis B sAg positivity. 64% had hepatitis B sAb\u2009\u2265\u200910mIU.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In a cohort of attendees to an HIV clinic in a large urban setting, the susceptibility to several common vaccine preventable viral infections, in particular MMR and hepatitis A and B, was high.\u00a0These results highlight the importance of proactive screening and immunisation to help protect this high risk patient group against vaccine preventable diseases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07487-z","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T13:04:58Z","timestamp":1656507898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Changing demographics and immunity to vaccine preventable diseases in people with HIV in Ireland"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9976-8033","authenticated-orcid":false,"given":"C.","family":"Kerr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Coughlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. J.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bergin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"issue":"1","key":"7487_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/QAD.0b013e32834dcf27","volume":"26","author":"Z Yin","year":"2012","unstructured":"Yin Z, Rice BD, Waight P, Miller E, George R, Brown AE, et al. Invasive pneumococcal disease among HIV-positive individuals, 2000\u20132009. AIDS. 2012;26(1):87\u201394.","journal-title":"AIDS"},{"key":"7487_CR2","doi-asserted-by":"crossref","unstructured":"Gordon MA, Feasey NA, Nyirenda TS, Graham SM. Nontyphoid Salmonella Disease. Hunter's tropical medicine and emerging infectious diseases. Elsevier; 2020. p. 500\u20136.","DOI":"10.1016\/B978-0-323-55512-8.00049-1"},{"issue":"9349","key":"7487_CR3","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","volume":"360","author":"CL Thio","year":"2002","unstructured":"Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Mu\u00f1oz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort Study (MACS). Lancet. 2002;360(9349):1921\u20136.","journal-title":"Lancet"},{"issue":"16","key":"7487_CR4","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/jnci\/djp205","volume":"101","author":"AK Chaturvedi","year":"2009","unstructured":"Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst. 2009;101(16):1120\u201330.","journal-title":"J Natl Cancer Inst"},{"issue":"S3","key":"7487_CR5","doi-asserted-by":"publisher","first-page":"s2","DOI":"10.1111\/hiv.12424","volume":"17","author":"AM Geretti","year":"2016","unstructured":"Geretti AM, Brook G, Cameron C, Chadwick D, French N, Heyderman R, et al. British HIV association guidelines on the use of vaccines in HIV-positive adults 2015. HIV Med. 2016;17(S3):s2\u201381.","journal-title":"HIV Med"},{"issue":"3","key":"7487_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40121-017-0166-x","volume":"6","author":"NF Crum-Cianflone","year":"2017","unstructured":"Crum-Cianflone NF, Sullivan E. Vaccinations for the HIV-infected adult: a review of the current recommendations, part I. Infect Dis Ther. 2017;6(3):303\u201331.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"7487_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40121-017-0165-y","volume":"6","author":"NF Crum-Cianflone","year":"2017","unstructured":"Crum-Cianflone NF, Sullivan E. Vaccinations for the HIV-infected adult: a review of the current recommendations, part II. Infect Dis Ther. 2017;6(3):333\u201361.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"7487_CR8","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44\u2013100.","journal-title":"Clin Infect Dis"},{"key":"7487_CR9","unstructured":"National Immunisation Advisory Committee. Immunisation guidelines for Ireland. 336. 2013."},{"issue":"5","key":"7487_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/hiv.12600","volume":"19","author":"L Ryom","year":"2018","unstructured":"Ryom L, Boesecke C, Bracchi M, Ambrosioni J, Pozniak A, Arribas J, et al. Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0. HIV Med. 2018;19(5):309\u201315.","journal-title":"HIV Med."},{"key":"7487_CR11","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.33.1700641","author":"P Ndumbi","year":"2018","unstructured":"Ndumbi P, Freidl GS, Williams CJ, M\u00e5rdh O, Varela C, Avell\u00f3n A. Hepatitis A outbreak disproportionately affecting men who have sex with men (MSM) in the European Union and European Economic Area, June 2016 to May 2017. Euro Surveill. 2018. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018.23.33.1700641.","journal-title":"Euro Surveill"},{"key":"7487_CR12","unstructured":"World Health Organization. Immunization, vaccines and biologicals: measles. 2014."},{"issue":"42","key":"7487_CR13","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.15585\/mmwr.mm6642a6","volume":"66","author":"A Dabbagh","year":"2017","unstructured":"Dabbagh A, Patel MK, Dumolard L, Gacic-Dobo M, Mulders MN, Okwo-Bele J-M, et al. Progress toward regional measles elimination\u2014worldwide, 2000\u20132016. MMWR Morb Mortal Wkly Rep. 2017;66(42):1148.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"45","key":"7487_CR14","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.15585\/mmwr.mm6645a4","volume":"66","author":"GB Grant","year":"2017","unstructured":"Grant GB, Reef SE, Patel M, Knapp JK, Dabbagh A. Progress in rubella and congenital rubella syndrome control and elimination\u2014Worldwide, 2000\u20132016. MMWR Morb Mortal Wkly Rep. 2017;66(45):1256.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"7487_CR15","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.vaccine.2019.04.019","volume":"37","author":"FC Pacheco","year":"2019","unstructured":"Pacheco FC, Fran\u00e7a GVA, Elidio GA, Domingues C, de Oliveira C, Guilhem DB. Trends and spatial distribution of MMR vaccine coverage in Brazil during 2007\u20132017. Vaccine. 2019;37(20):2651\u20135.","journal-title":"Vaccine"},{"issue":"13","key":"7487_CR16","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.vaccine.2019.02.030","volume":"37","author":"RB Kennedy","year":"2019","unstructured":"Kennedy RB, Ovsyannikova IG, Thomas A, Larrabee BR, Rubin S, Poland GA. Differential durability of immune responses to measles and mumps following MMR vaccination. Vaccine. 2019;37(13):1775\u201384.","journal-title":"Vaccine"},{"key":"7487_CR17","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820001296","volume":"148","author":"CJ Waugh","year":"2020","unstructured":"Waugh CJ, Willocks LJ, Templeton K, Stevenson J. Recurrent outbreaks of mumps in Lothian and the impact of waning immunity. Epidemiol Infect. 2020;148: e131.","journal-title":"Epidemiol Infect"},{"issue":"10","key":"7487_CR18","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/infdis\/jis568","volume":"206","author":"M Kontio","year":"2012","unstructured":"Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis. 2012;206(10):1542\u20138.","journal-title":"J Infect Dis"},{"issue":"6","key":"7487_CR19","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jiph.2017.01.019","volume":"10","author":"C Sadlier","year":"2017","unstructured":"Sadlier C, O\u2019Rourke A, Carr A, Bergin C. Seroepidemiology of hepatitis A, hepatitis B and varicella virus in people living with HIV in Ireland. J Infect Public Health. 2017;10(6):888\u201390.","journal-title":"J Infect Public Health"},{"key":"7487_CR20","unstructured":"HSE Health Protection Surveillance Centre. HIV in Ireland, 2018. Dublin: HSE HPSC; 2019. https:\/\/www.hpsc.ie\/a-z\/hivandaids\/hivdataandreports\/2018reports\/HIV_2018_finalrev.pdf."},{"issue":"1","key":"7487_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jinf.2010.04.004","volume":"61","author":"J Molton","year":"2010","unstructured":"Molton J, Smith C, Chaytor S, Maple P, Brown K, Johnson M, et al. Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. J Infect. 2010;61(1):73\u201380.","journal-title":"J Infect"},{"issue":"45","key":"7487_CR22","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.1016\/j.vaccine.2014.07.114","volume":"32","author":"K Grabmeier-Pfistershammer","year":"2014","unstructured":"Grabmeier-Pfistershammer K, Poeppl W, Herkner H, Touzeau-Roemer V, Huschka E, Rieger A, et al. High need for MMR vaccination in HIV infected adults in Austria. Vaccine. 2014;32(45):6020\u20133.","journal-title":"Vaccine"},{"issue":"4","key":"7487_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/occmed\/46.4.289","volume":"46","author":"J Gallagher","year":"1996","unstructured":"Gallagher J, Quaid B, Cryan B. Susceptibility to varicella zoster virus infection in health care workers. Occup Med (Lond). 1996;46(4):289\u201392.","journal-title":"Occup Med (Lond)"},{"issue":"1","key":"7487_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S1201-9712(02)90128-1","volume":"6","author":"M Popara","year":"2002","unstructured":"Popara M, Pendle S, Sacks L, Smego RA Jr, Mer M. Varicella pneumonia in patients with HIV\/AIDS. Int J Infect Dis. 2002;6(1):6\u20138.","journal-title":"Int J Infect Dis"},{"key":"7487_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2019.e00667","volume":"19","author":"WC Lin","year":"2020","unstructured":"Lin WC, Chang C, Ko MC, Lin SM. A fatal case of severe systemic varicella zoster infection in a patient with chronic use of immunosuppressive agents for cutaneous vasculitis. IDCases. 2020;19: e00667.","journal-title":"IDCases"},{"issue":"4","key":"7487_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF02937419","volume":"167","author":"E Rajan","year":"1998","unstructured":"Rajan E, O\u2019Farrell B, Shattock AG, Fielding JF. Hepatitis A in urban Ireland. Ir J Med Sci. 1998;167(4):231\u20133.","journal-title":"Ir J Med Sci"},{"issue":"1","key":"7487_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1186\/s12879-019-4235-5","volume":"19","author":"J Patterson","year":"2019","unstructured":"Patterson J, Abdullahi L, Hussey GD, Muloiwa R, Kagina BM. A systematic review of the epidemiology of hepatitis A in Africa. BMC Infect Dis. 2019;19(1):651.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"7487_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.respe.2017.05.009","volume":"65","author":"W Guenifi","year":"2017","unstructured":"Guenifi W, Laouamri S, Lacheheb A. Changes in prevalence of hepatitis A and associated factors in Setif-Algeria. Rev Epidemiol Sante Publique. 2017;65(6):437\u201342.","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"6","key":"7487_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216033","volume":"14","author":"A Haeri Mazanderani","year":"2019","unstructured":"Haeri Mazanderani A, Motaze NV, McCarthy K, Suchard M, du Plessis NM. Hepatitis A virus seroprevalence in South Africa\u2014estimates using routine laboratory data, 2005\u20132015. PLoS ONE. 2019;14(6): e0216033.","journal-title":"PLoS ONE"},{"key":"7487_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-22330-8_9","volume-title":"Global epidemiology of hepatitis B virus infection. Hepatitis B virus in human diseases","author":"D Lavanchy","year":"2016","unstructured":"Lavanchy D, Kane M. Global epidemiology of hepatitis B virus infection. Hepatitis B virus in human diseases. Cham: Springer; 2016. p. 187\u2013203."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07487-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07487-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07487-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T13:06:41Z","timestamp":1656508001000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07487-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7487"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07487-z","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"10 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Full ethical approval for this research was granted by the St. James\u2019s Hospital\/Tallaght University Hospital research ethics committee on 9<sup>th<\/sup> March 2020 (REC: 2020-02 List 7). The requirement for explicit consent in the Health Research Regulations does not apply in relation to a retrospective chart review study. Data was anonymised before its use.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have any conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"582"}}